Clinical trial
Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's…
NCT00203060 · Teva Neuroscience, Inc., Industry · Completed
Key facts
| NCT number | NCT00203060 |
|---|---|
| Title | Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa |
| Official title | A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial For The Efficacy, Tolerability And Safety Of Two Doses Of Rasagiline Mesylate In Early Parkinson's Disease (PD) Patients Not Treated With Levodopa |
| Lead sponsor | Teva Neuroscience, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | Rasagiline Mesylate, placebo |
| Enrollment | 404 |
| Start date | Jul 1, 1997 |
| Primary completion | Jul 1, 2000 |
| Completion | Jul 1, 2000 |
| First posted | Sep 20, 2005 |
| Last update posted | Apr 12, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: